Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
HighCape Partners
AddedFeb 15, 2024
UpdatedJun 28, 2026
HighCape Partners

HighCape Partners

Operating

HighCape, a growth equity firm, invests in and transforms life sciences companies into scalable, sustainable businesses.

Location
Baltimore, MD, US
Founded
2013
Firm
Compare
Portfolio
Employees
Website

HighCape Partners is a growth equity firm specializing in investments within the life sciences sector. The firm focuses on companies that are commercializing high-margin products, aiming to transform them into scalable commercial entities. HighCape typically participates in various investment stages, including Seed, Series B, Series E, and beyond, with a notable presence in Series B rounds.

Notable portfolio companies include Cybrexa, Elutia, Modifi Bio, and Zipline Medical. HighCape's key partners are experienced in scaling businesses into sustainable entities with multiple exit strategies. The firm offers unique value-add services that help portfolio companies achieve commercial scalability and sustainability, leveraging their deep industry expertise and strategic guidance.

HighCape Partners - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments11
Current Portfolio Count6
Total Portfolio Exits0

Top Investment Stages

Series B4 (40.0%)
Seed2 (20.0%)
Series Unknown2 (20.0%)
Post Ipo Equity1 (10.0%)
Series E1 (10.0%)

Stage Mix

Series B 40%Seed 20%Series Unknown 20%Post Ipo Equity 10%Series E 10%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Modifi Bio logo

Modifi Bio

Elutia logo

Elutia

Cybrexa logo

Cybrexa

Alphina Therapeutics logo

Alphina Therapeutics

convexity scientific logo

convexity scientific

Zipline Medical logo

Zipline Medical

HighCape Partners - Classification

Also Known As
  • Highcape Partners, L.P.
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end